Stockpolly
Search
SABS · NASDAQ · Biotechnology

SAB Biotherapeutics (SABS)

Develops a fully human polyclonal-antibody therapy for newly diagnosed autoimmune diabetes.

$3.60
Pre-market−0.15 (−4.00%)
At close$3.75(+1.35%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue101000000000
Cost of revenue112111811110
Gross profit0−1−1−1−1−1−8−1−1−1−10
6181091093912151923
Research & development448788879111316
3152332334567
Selling & marketing0000000000−10
General & administrative3150000334577
Other expenses−1−10000−8−1−1−100
Operating income−5−19−11−10−11−10−11−10−13−16−20−23
0−4631−16058−111
Interest income000000001112
Interest expense000000000000
Other non-operating income04−6−3−11−60−581−1−1
Income before tax−5−23−5−7−10−11−5−1045−17−19−22
Net income from continuing operations−5−23−5−7−10−11−5−1045−17−19−22
Net income−5−23−5−7−10−11−5−1045−17−19−22
EPS, basic−$0.97−$3.86−$0.54−$0.79−$1.12−$1.23−$0.56−$1.09$4.26−$0.06−$0.35−$0.28
EPS, diluted−$0.97−$3.86−$0.54−$0.79−$1.12−$1.23−$0.56−$1.09$0.58−$0.81−$0.35−$0.28
Weighted average shares, basic5699999911485480
Weighted average shares, diluted5699999978485480
EBITDA−4−22−3−6−9−11−4−946−16−18−22
Depreciation & amortization112111111111
EBIT−5−23−5−7−10−11−5−1045−17−19−22